Additional subsets of patients where IL-1 therapy should be possibly taken into account include contraindications of traditional therapy with NSAIDs and glucocorticoids, such as active peptic ulcer, decompensated heart failure, and advanced chronic kidney disease, among others. This evidence concerns the gene IL1A and chronic kidney disease.